Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Nguyen DH and Taub DD | Inhibition of chemokine receptor function by membrane cholesterol oxidation. | 2003 | Exp. Cell Res. | pmid:14597406 |
Ahn KW and Sampson NS | Cholesterol oxidase senses subtle changes in lipid bilayer structure. | 2004 | Biochemistry | pmid:14730988 |
Finn DA et al. | The role of pregnane neurosteroids in ethanol withdrawal: behavioral genetic approaches. | 2004 | Pharmacol. Ther. | pmid:14761701 |
Lee HH et al. | Theaflavin-3,3'-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells. | 2004 | Carcinogenesis | pmid:14963012 |
Leyden J et al. | A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. | 2004 | J. Am. Acad. Dermatol. | pmid:14988688 |
Goodman PJ et al. | Implementation of the Prostate Cancer Prevention Trial (PCPT). | 2004 | Control Clin Trials | pmid:15020037 |
Gonzales E et al. | SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. | 2004 | J. Hepatol. | pmid:15030995 |
Frye CA et al. | Progesterone enhances motor, anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those deficient in type 1 5 alpha-reductase. | 2004 | Brain Res. | pmid:15033426 |
Brown GA and Sussman DO | A current review of medical therapy for benign prostatic hyperplasia. | 2004 | J Am Osteopath Assoc | pmid:15038398 |
Marberger M et al. | Optimising the medical management of benign prostatic hyperplasia. | 2004 | Eur. Urol. | pmid:15041103 |